Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis by F. Peyvandi et al.
IN FOCUS
Timing and severity of inhibitor development in recombinant
versus plasma-derived factor VIII concentrates: a SIPPET
analysis
F . PEYVANDI ,*† A . CANNAV O,* I . GARAGIOLA ,* R . PALLA ,* P . M. MANNUCCI , *† and
F . R . ROSENDAAL‡ FOR THE S IPPET STUDY GROUP1
*Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico and Luigi Villa
Foundation, Milan, Italy; †Department of Pathophysiology and Transplantation, Universita degli Studi di Milano, Milan, Italy; and
‡Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands
To cite this article: Peyvandi F, Cannavo A, Garagiola I, Palla R, Mannucci PM, Rosendaal FR, for the SIPPET Study Group. Timing and severity
of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. J Thromb Haemost 2018; 16:
39–43.
See also Fallon PG, Lavin M, O’Donnell JS. SIPPET: insights into factor VIII immunogenicity. This issue, pp 36–8.
Essentials
• Recombinant factor VIII (rFVIII) was contrasted with
plasma-derived FVIII (pdFVIII).
• In previously untreated patients with hemophilia A,
rFVIII led to more inhibitors than pdFVIII.
• Inhibitors with rFVIII developed earlier, and the peak
rate was higher than with pdFVIII.
• Inhibitors with rFVIII were more severe (higher titre)
than with pdFVIII.
Summary. Background: The development of neutralizing
antibodies (inhibitors) against factor VIII (FVIII) is the
most severe complication in the early phases of treatment
of severe hemophilia A. Recently, a randomized trial, the
Survey of Inhibitors in Plasma-Product Exposed Toddlers
(SIPPET) demonstrated a 2-fold higher risk of inhibitor
development in children treated with recombinant FVIII
(rFVIII) products than with plasma-derived FVIII
(pdFVIII) during the first 50 exposure days (EDs). Objec-
tive/Methods: In this post-hoc SIPPET analysis we
evaluated the rate of inhibitor incidence over time by every
5 EDs (from 0 to 50 EDs) in patients treated with different
classes of FVIII product, made possible by a frequent test-
ing regime. Results: The highest rate of inhibitor develop-
ment occurred in the first 10 EDs, with a large contrast
between rFVIII and pdFVIII during the first 5 EDs: hazard
ratio 3.14 (95% confidence interval [CI], 1.01–9.74) for all
inhibitors and 4.19 (95% CI, 1.18–14.8) for high-titer inhi-
bitors. For patients treated with pdFVIII, the peak of inhi-
bitor development occurred later (6–10 EDs) and lasted for
a shorter time. Conclusion: These results emphasize the
high immunologic vulnerability of patients during the earli-
est exposure to FVIII concentrates, with the strongest
response to recombinant FVIII products.
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Introduction
The development of alloantibodies (inhibitors) neutralizing
factor VIII (FVIII) coagulant activity represents the main
complication of treatment of hemophilia A. It occurs in
approximately one-third of previously untreated patients
(PUPs) with severe disease and causes substantial morbidity
with a major increase in cost of treatment [1–3]. Inhibitor
development has a multi-causal etiology [4–7], and it usually
occurs in young children during the first 20–30 exposure
days (EDs) to FVIII replacement [8–11]. Recently, the ran-
domized SIPPET trial demonstrated that in these early
stages of treatment the risk of inhibitor development was
nearly 2-fold higher in patients treated with recombi-
nant FVIII products (rFVIII) than in those treated with
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plasma-derived FVIII (pdFVIII), with the majority of inhi-
bitors occurring during the first 20 EDs [12].
There are few data available on the time course of inhibi-
tor development after FVIII exposure [8–11] because of the
absence of studies with frequent serial inhibitor measure-
ments. In the SIPPET study, inhibitor monitoring was per-
formed at strict, frequent and standardized time-intervals in
all patients [12]. This strict monitoring schedule allowed us
to perform an analysis to investigate the risk of inhibitor
development in the early risk period to assess whether there
was a difference in the time course of inhibitor development
between patients treated with the classes of pdFVIII or
rFVIII products. In addition, we assessed the severity of
inhibitors for the two product classes.
Study design
This is a post hoc analysis performed in the frame of the SIP-
PET randomized trial [12]. Two hundred and fifty-one male
patients with severe hemophilia A aged < 6 years, negative
for inhibitor measurement, never exposed to FVIII concen-
trates, and not or minimally treated (less than 5 EDs) with
blood components (whole blood, fresh frozen plasma,
packed red cells, platelets or cryoprecipitate) were included
[12]. Patients were randomized to treatment with a single
brand of a rFVIII or pdFVIII product containing von
Willebrand factor and were followed for the first 50 EDs, or
until 3 years after enrolment or study termination or inhibi-
tor development, whichever occurred first. Thirty-five
patients who had not reached 50 EDs at the time of study
termination were censored, and of those 25 had less than 20
EDs. Data were also collected on self-reported family his-
tory of hemophilia and inhibitors, age at first treatment,
country site, previous exposure to blood components and
FVIII gene mutations (for more details, see [12]).
Methods and timing of inhibitor testing were as
previously reported [12,13]. Briefly, patients who received
on-demand treatment underwent inhibitor testing every
3–4 EDs during the first 20 infusions, then every 10 EDs
or every 3 months. Patients who received prophylaxis
underwent inhibitor testing every 2 weeks. Additional
testing was carried out at the time of clinical suspicion of
inhibitor and for all patients after study completion. In
case of inhibitor occurrence, levels were confirmed on a
second sample within 14 days after the first positivity,
and then monthly for 6 months.
Kaplan–Meier survival analyses were performed to
estimate cumulative incidences for all and high-titer inhi-
bitors by FVIII treatment class, and incidence rates were
compared with Cox regression survival analyses taking
into account as covariates FVIII gene mutations, self-
reported family history of hemophilia or inhibitor, age at
first treatment (in months), treatment modality, ethnicity,
country and treatment center. To study the risk over
time, we calculated the proportion developing an inhibi-
tor during intervals of 5 EDs, accounting for those having
an event or being censored during an interval, as by a
standard life-table technique. Confidence intervals were
derived from the binomial distribution according to Wil-
son [14]. Adjustments in multivariate Cox models were in
a bivariate manner, as well as with full models. Confi-
dence intervals were derived from this model. Statistical
analyses were performed within SPSS, version 23.0 (IBM
Corp., Armonk, NY, USA).
Results and discussion
Seventy-six of 251 patients developed an inhibitor, 50 of
which were high titer. All inhibitors occurred before 39
EDs and 90% (68/76) within 20 EDs. All high-titer inhi-
bitors occurred before 34 EDs and 90% (45/50) within 16
EDs for patients in both arms. The cumulative incidence
of all inhibitors during the first 50 EDs was 35.4% (95%
confidence interval [CI], 28.9–41.9), and for high-titer
inhibitors it was 23.3% (95% CI, 17.6–29.0) [12].
When the rate of inhibitor development was investi-
gated over time, in the group of patients randomized to a
rFVIII product, inhibitors occurred earlier than with
pdFVIII, whereas the rate per short time-interval
remained high until 20 EDs; for patients treated with a
pdFVIII product the peak was lower, occurred later and
lasted for a shorter time than with rFVIII. Table 1 shows
the development of inhibitors over short time-intervals of
5 EDs for each of the FVIII product classes. In detail, 16
of the 76 (21%) inhibitors developed during the first 5
EDs; that is, 12 of the 47 (26%) patients treated with
rFVIII for an incidence of 9.5%, and four of 29 (14%)
inhibitors in patients treated with pdVIII for an incidence
of 3.2%. In patients treated with rFVIII, all 12 inhibitors
that occurred early (0–5 EDs) were high titer (in patients
treated with pdFVIII, three of four (75%) were high
titer). The hazard ratio (HR) was particularly high during
this early exposure period, both for all (HR, 3.14; 95%
CI, 1.01–9.74) and high-titer inhibitors (HR, 4.19; 95%
CI, 1.18–14.84) (Table 2), showing a 3- to 4-fold
increased risk of inhibitor for rFVIII products in the ear-
liest phase of treatment, with an absolute difference in
inhibitor development of 6.3%. During the interval of 6–
10 EDs the absolute difference in inhibitor development
was 5%, and the relative rate attenuated (HR, 1.42; 95%
CI, 0.72–2.80). After this early treatment period, the dif-
ference between the two classes remained but became less
pronounced. After bivariate adjustment for putative con-
founders, the risk of inhibitor development during the
first 5 EDs did not change (Table 2), nor in a full model
adjusted for age, mutation, center, family history and pre-
vious exposure to blood products (all inhibitors, HR 3.30,
95% CI 0.87–12.52; high-titer inhibitors, HR 4.77, 95%
CI 1.01–22.50).
Severity of the immunogenic effect was studied by
using different cut-off values, in Bethesda units, for (high-
titer) inhibitors (Table 3). Whereas the hazard ratio was
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1.87 (95% CI, 1.17–2.96) for values exceeding 0.6 BU
(which captures all inhibitors, ranging in peak levels from
0.7 to 1850 BU), the hazard steadily increased for more
severe inhibitors, with hazard ratios of 4.74 (95% CI,
1.54–14.08) for titers exceeding 50 BU, and 8.87 (95%
CI, 2.04–38.87) for titers over 100 BU.
The development of anti-FVIII neutralizing antibodies
is the most serious complication of FVIII replacement
therapy [1–3]. The class of FVIII products and its role in
the occurrence of this complication have been discussed
and analyzed in different observational studies and meta-
analyses [8–11,15,16], as well as in the frame of a single
randomized clinical trial [12]. SIPPET showed a higher
immunogenicity of rFVIII products than of pdFVIII con-
taining von Willebrand factor during the first 50 EDs,
and confirmed that most inhibitors develop within the
first 20 EDs, as previously suggested in several observa-
tional studies [8–11]. In the latter, lack of data stemming
from protocolized and centralized inhibitor monitoring
did not allow time-dependent analyses. SIPPET, by
means of uniquely frequent follow-up monitoring and
centralized inhibitor measurement, allowed a precise
assessment of the timing of the FVIII antibody develop-
ment. Whereas we confirmed that almost 90% of
inhibitors occurred during the first 20 EDs for both treat-
ment arms, the immune response to rFVIII occurred
earlier, had a higher peak incidence, and lasted longer
Table 1 Risk of inhibitor incidence over time. (A) Shows the risk of all inhibitors in relation to the class of FVIII products (recombinant or
plasma derived). (B) Shows the risk of high-titer inhibitors
ED
Plasma-derived FVIII Recombinant FVIII
Number
at risk*
Number of
inhibitors
Incidence
% (95% CI)
Number
at risk*
Number
of inhibitors
Incidence
% (95% CI)
(A) All inhibitors
0–5 125 4 3.2 (1.3–7.9) 126 12 9.5 (5.5–15.9)
6–10 112 15 13.4 (8.3–20.9) 103 19 18.4 (12.1–27.0)
11–15 92 3 3.3 (1.1–9.2) 76 6 7.9 (3.7–16.2)
16–20 84 4 4.8 (1.9–11.6) 65 5 7.7 (3.3–16.8)
21–25 76 0 0.0 (0–4.8) 56 2 3.6 (1.0–12.1)
26–30 65 2 3.1 (0.8–10.5) 52 0 0.0 (0–6.9)
31–35 58 1 1.7 (0.3–9.1) 48 2 4.2 (1.2–14.0)
36–40 55 0 0.0 (0–6.5) 43 1 2.3 (0.4–12.1)
(B) High-titer inhibitors
0–5 125 3 2.4 (0.8–6.8) 126 12 9.5 (5.5–15.9)
6–10 112 12 10.7 (6.2–17.8) 103 11 10.7 (6.1–18.1)
11–15 92 2 2.2 (0.6–7.6) 76 4 5.3 (2.1–12.8)
16–20 84 2 2.4 (0.7–8.3) 65 2 3.1 (0.8–10.5)
21–25 76 0 0.0 (0–4.8) 56 1 1.8 (0.3–9.4)
26–30 65 0 0.0 (0–5.6) 52 0 0.0 (0–6.9)
31–35 58 1 1.7 (0.3–9.1) 48 0 0.0 (0–7.4)
36–40 55 0 0.0 (0–6.5) 43 0 0.0 (0–8.2)
*Patients at risk at the beginning of the time interval. CI, confidence interval.
Table 2 Cox regression for inhibitor development by class of FVIII
products during 0–5 exposure days with plasma-derived FVIII as the
reference category
Adjustment variable All inhibitors
High-titer
inhibitors
None 3.14 (1.01–9.74) 4.19 (1.18–14.84)
Age 3.19 (1.03–9.91) 4.23 (1.19–15.02)
Mutation 2.93 (0.93–9.20) 3.90 (1.09–13.99)
Country 3.16 (1.02–9.80) 4.22 (1.19–14.97)
Ethnicity 3.22 (1.04–10.0) 4.30 (1.21–15.23)
Family history of hemophilia 2.95 (0.94–9.28) 3.91 (1.09–14.04)
Family history of inhibitor 2.98 (0.96–9.24) 3.97 (1.12–14.08)
Previous exposure to blood
components
3.12 (1.01–9.68) 4.17 (1.18–14.79)
Treatment regimen 3.14 (1.01–9.76) 4.15 (1.17–14.75
Treatment center 3.39 (1.08–10.62) 4.49 (1.26–16.10)
Hazard ratio compares the incidence of inhibitor development
among patients treated with recombinant products and those treated
with plasma-derived products.
Table 3 Hazard ratio for inhibitors for rFVIII vs. pdFVIII with
increasing Bethesda units cut-offs
Cut-off (BU) HR 95% CI
0.6 1.87 1.17–2.96
2 1.67 1.02–2.75
4 1.71 1.00–2.94
8 2.12 1.16–3.89
12 2.26 1.19–4.29
16 2.71 1.29–5.66
20 2.75 1.27–5.98
30 3.05 1.28–7.27
40 3.16 1.24–8.01
50 4.74 1.54–14.08
100 8.87 2.04–38.57
Hazard ratios (HRs) with 95% confidence intervals (95% CIs) are
given for rFVIII vs. pdFVIII for increasing cut-off values (Bethesda
units [BU]), with levels exceeding these values as the outcome.
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than in patients treated with pdFVIII. During the first 5
EDs, patients treated with recombinant products had a
3–4-fold higher risk of inhibitor development, including
high-titer inhibitors, than patients treated with pdFVIII.
When we investigated the severity of the inhibitor, the
risk conferred by rFVIII relative to pdFVIII increased
steadily over increasing cut-off BU levels, demonstrating
that the difference in immunogenicity between rFVIII and
pdFVIII is quantitative, as well temporal and qualitative.
The strong immunogenic effect of rFVIII was also shown
in a previous analysis, where we reported that patients
with a low genetic risk of inhibitors (as a result of mis-
sense mutations where some defective protein is secreted)
have a low risk of inhibitors when treated with pdFVIII,
whereas with rFVIII this protection disappears [17].
A limitation of the current analysis is that it was based
on a relatively small sample, hemophilia being a rare dis-
order. Nevertheless, the pattern of an earlier, longer last-
ing risk period was clear. A major strength is that the
analysis was performed in a randomized study, in which
confounding by extraneous factors is avoided, as was evi-
dent from the absence of an effect of adjustment. A
detailed discussion of strengths and weaknesses of SIP-
PET can be found elsewhere [18].
Different mechanisms may play a role in the fast and
strong immune reaction to recombinant FVIII products.
It is well established that post-translational modifications
(e.g. glycosylation) occur with these products [19,20], and
that a fraction of rFVIII is unable to bind to von Wille-
brand factor, potentially decreasing FVIII recognition by
antigen presenting cells [21]. Furthermore, pdFVIII prod-
ucts may contain immunomodulating human proteins,
which may play a role in inducing greater FVIII tolerance
[22,23]. However, it remains to be elucidated why the
immunogenicity of rFVIII also lasts longer than with
pdFVIII, which may be related to environmental stimuli.
The fast recognition of rFVIII products by the immune
system in the first few days of replacement therapy, and
the much stronger response than with pdFVIII in relation
to inhibitor titers, corroborates the notion that their high
inhibitor risk is a result of an increased immunogenicity.
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